Evidence map›Paper›PMID 35083086›Full record

ReviewBiochemistry research international2022

Recent Progress in Nanobiosensors for Precise Detection of Blood Glucose Level.

Haniye Khosravi Ardakani, Mitra Gerami, Mostafa Chashmpoosh, Navid Omidifar, Ahmad Gholami

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biochemistry research international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Haniye Khosravi ArdakaniBiotechnology Research Center, University of Medical Sciences, Shiraz, Iran.
Mitra GeramiBiotechnology Research Center, University of Medical Sciences, Shiraz, Iran.
Mostafa ChashmpooshDepartment of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Navid OmidifarDepartment of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Ahmad GholamiPharmaceutical Sciences Research Center, University of Medical Sciences, Shiraz, Iran.ORCID https://orcid.org/0000-0003-1851-159X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes mellitus (DM) follows a series of metabolic diseases categorized by high blood sugar levels. Owing to the increasing diabetes disease in the world, early diagnosis of this disease is critical. New methods such as nanotechnology have made significant progress in many areas of medical science and physiology. Nanobiosensors are very sensible and can identify single virus particles or even low concentrations of a material that can be inherently harmful. One of the main factors for developing glucose sensors in the body is the diagnosis of hypoglycemia in individuals with insulin-dependent diabetes. Therefore, this study aimed to evaluate the most up-to-date and fastest glucose detection method by nanosensors and, as a result, faster and better treatment in medical sciences. In this review, we try to explore new ways to control blood glucose levels and treat diabetes. We begin with a definition of biosensors and their classification and basis, and then we examine the latest biosensors in glucose detection and new biosensors applications, including the artificial pancreas and updating quantum graphene data.

Identifiers

PMID35083086
PMCPMC8786499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.